Shilpa Medicare Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Margin squeeze from both sides: Gross margin fell 700 bps YoY to 61% as key products faced simultaneous pricing pressure and input cost hikes, driving EBITDA margin down to 11%.
• The API business is under structural pressure: Industry-wide selling price declines and elevated costs forced the company to accelerate yield improvements, backward integration, and capacity expansion to defend margins.
• The investment phase is over; the crystallization phase begins: Management declared that enough investment has been made across biologics, albumin, films, and peptides, and the focus now shifts to monetizing those assets.
• Import alert remediation is complete but the clock is out of management's hands: All remediation measures are done, third-party audits found no data integrity issues, and the company is waiting for FDA reinspection with no timeline visibility.
• What to watch next quarter: Whether the deferred Q1 revenues actually land in Q2, the pace of API margin recovery from cost-side measures, and any progress on biologics CDMO revenue ramp-up.

Margin Erosion: The Double Squeeze

• Pricing pressure hit both segments: Some key products in API and formulations faced declining selling prices during the quarter, compressing the top end of the P&L.
• Cost hikes compounded the damage: Input costs rose on certain major products at the same time, so the margin hit came from both revenue and cost lines simultaneously.
• Gross margin fell 700 bps YoY: From 68% to 61%, the single largest driver of the EBITDA decline from ₹34 crore to ₹29 crore.
• Cost rationalization provided a partial offset: Proactive measures and a reduction in remedial costs for the Jadcherla site helped contain the EBITDA damage, but not enough to hold margins flat.
• API margin recovery is a cost-side story: Management is working on process optimization, yield improvement, backward integration, larger batch sizes, and capacity expansion to spread fixed costs, while acknowledging that selling price pressure may not ease immediately.
• One-off revenue flattered Other API: Part of Q1 Other API revenue was a one-off trading item linked to a license expiring on 30 June and moving to the next Shilpa Pharma license; this is not likely to repeat.

Alpesh Dalal: "the main reasons, you know, why we witnessed these erosions was on account of pricing pressure on some of our key products both in the API and formulation segment as well as, you know, where we also witnessed some cost hikes in some of our major products."

API Business: Restructuring Under Pressure

• The API industry is in a downcycle: Selling prices are declining and costs are rising across the sector; Shilpa is not alone in facing this squeeze.
• Slump sale completed, subsidiary standing alone: The API business was transferred to a wholly owned subsidiary on a slump sale basis, generating a ₹63 crore gain and ₹104 crore profit from discontinued operations in standalone financials.
• IPO exploration is on the table: The board has approved exploring an IPO for the API subsidiary if it proves the most appropriate option, but management wants the entity to first stabilize and generate independent performance before any monetization decision.
• Strategic diversification underway: The company is reducing dependency on the established Onco segment by adding niche high-value Non-Onco products, peptides, polymers, CDMO, and intermediates.
• Backward integration to reduce China dependency: Work is ongoing to manufacture in-house intermediates that currently have 100% China dependency, using conventional or flow chemistry.
• Q1 softness had a stockpiling explanation: Management's gut feel is that API customers built up inventory during COVID and are now drawing down those stocks as supply chains ease; Q1 is also historically soft for Shilpa.
• Revenue deferral added to Q1 weakness: Part of Q1 dispatches could not be recognized as revenue under IND AS requirements and were pushed into Q2.
• CRAMS is winding down slowly: The CRAMS business is continuing but gradually declining; no inventory is held on books, so there is no risk of write-offs.

Vishnukant Bhutada: "globally, it is known that if Shilpa gives the product, then it is compliant with all global standards including the non-infringement if it is required."

Biologics, Albumin & Films: The Monetization Pivot

• The investment phase is complete: Management stated explicitly that enough investment has been made across biologics, recombinant albumin, transdermal films, and peptides, and the focus now shifts to crystallizing each segment.
• Biologics facility is still a cost center: The Dharwad plant has not started real commercial operations and is currently a negative contributor; the company is exploring CMO/CDMO opportunities to generate revenue and cover operational expenses from H2 FY23 onward.
• Adalimumab launch targeted for Q3 in India: High-concentration Adalimumab has completed Phase-3 using European R&D and been submitted to authorities; management expects it to be the first launch in India.
• Aflibercept cleared for clinical trials: RCGM approval received, claimed as the first company to get this clearance; Phase-3 study to initiate next month.
• Biologics strategy is shifting to co-development: Having established in-house R&D and manufacturing credentials, the company now intends to pursue co-development, manufacturing, and CDMO opportunities rather than going it alone on every program.
• Recombinant albumin Phase-1 cleared: Government permission received to start the Phase-1 trial; management expects to begin by end of year and complete within nine months.
• Albumin manufacturing scale-up achieved: Product successfully shifted from 200-liter to 1,000-liter scale; patents granted in the US and Europe.
• Albumin Capex is the largest remaining spend: A dedicated 150,000-liter fermentation facility is being set up near Raichur with total investment of ~₹400 crore, of which ₹250–280 crore remains to be invested.
• Albumin excipient sales targeted for next year: Once the DMF is completed, management expects to sell excipient-grade albumin by 2024 or 2025.
• Film and transdermal facility received UK MHRA clearance: The Bengaluru facility was audited with zero major or minor observations.
• Film formulation revenue expected in FY24–25: Products have been filed in Europe and US filings are planned this year or next; management expects good revenue generation once approvals come through.
• Peptide pipeline building toward FY24–25 sales: Two exhibit batches to complete this year, four more next year; products selected based on in-house requirements first, then external market opportunities.

Vishnukant Bhutada: "We wanted to establish first on our own and show to the world that we have enough capability, enough manufacturing capabilities including the R&D development strength. Now with this, the credentials, probably, now we will try to see that the co-development model or the manufacturing or CDMO, there are several opportunities in this, but being the biologic, it will go a little slow."

Import Alert & Regulatory: Waiting on the FDA

• Remediation is effectively complete: Almost all measures expected by the FDA have been implemented; third-party audits are done and submitted to the agency.
• No data integrity issues found: Consultants' retrospective review of all ANDAs has not suggested any recall, indicating no data integrity, microbial, or sterility challenges.
• The facility is still operating partially: The Jadcherla SEZ formulation site remains under import alert but is still permitted to export three (or five) products to the US market and is also selling to European markets; it is not a negative contributor to the bottom line.
• Reinspection timing is unknown: Management is continuously updating the FDA on remediation progress but cannot predict when an inspection will be scheduled.
• Site transfer de-risking is underway: Critical products are being shifted to various USFDA-approved CMO sites for both oral and injectable dosage forms, but only for products with commercial potential, not the entire portfolio.

Vishnukant Bhutada: "That shows that the quality was never compromised by the Shilpa, because this all reports also, the third party audits reports also to be simultaneously submitted to the FDA."

Formulations: Domestic Push, Europe Pressure, Licensing Variability

• European business is concentrated and under pressure: A large chunk of European formulation revenue comes from one product that has witnessed pricing pressure, causing revenues to settle at a lower level.
• Domestic strategy is a hybrid model: The company is pursuing B2B, B2C, tendering, government, and hospital channels simultaneously, with product-by-product decisions on exclusivity versus parallel licensing.
• Licensing revenue is lumpy by nature: Q1 included ~₹17 crore in license fees with no further permit rights revenue; milestone-based deals mean revenues vary quarter to quarter depending on deal structure and timing.
• Management targets licensing continuity: The aspiration is that the run rate seen in recent quarters should at least continue, but this is entirely dependent on deals struck.
• US and Europe growth tied to pipeline approvals: As the pipeline grows and newer products come in, revenues in both territories should see an uptick, but the timing depends on regulatory approvals.
• Ophthalmic segment seeking partners: Two 505B2s and two complex products have been developed; the company is looking for partners with appropriate manufacturing set-ups to license them out before making further investments.

Alpesh Dalal: "It would really be dependent on the kind of deals that we keep striking at various points in time, right? So, in certain cases, you are able to get a decent upfront and then, you know, the later milestones could be slightly lower. In certain cases, the upfront might be slightly lower but then subsequent myself could be fairly heavy depending on the commercial situation."

Cash Flow, Capex & Balance Sheet

• Capex is heavily skewed toward albumin: Of ₹53 crore in Q1 Capex, ₹29 crore went to the albumin business; API received ₹15 crore, biologics ₹6 crore, and formulations only maintenance Capex.
• No further major biologics Capex planned: The investment phase for the Dharwad facility is complete.
• API Capex will run at ₹40–50 crore per year: Regular capacity expansion will continue at this average annual rate.
• Formulation Capex is minimal: No significant Capex is planned beyond maintenance.
• Debt reduction is a stated priority: Management intends to gradually bring debt down, aiming to retain only working-capital-related loans and remove everything else, in line with monetization plans.
• Multiple cash flow bridges being explored: Options include the API subsidiary IPO, licensing of formulation OpEx, co-development models, and licensing of albumin or monoclonal antibodies, all being pursued concurrently.
• Asset turnover upside from formulations and biologics: When these businesses start peaking, they can turn assets many more times than the API business can.

Guidance & Commitments

Key Metrics